2024
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Kinslow C, Roy S, Iwamoto F, Brown P, DeStephano D, Canoll P, Qureshi S, Gallito M, Sisti M, Bruce J, Horowitz D, Kachnic L, Neugut A, Yu J, Mehta M, Cheng S, Wang T. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology 2024, noae102. PMID: 38943513, DOI: 10.1093/neuonc/noae102.Peer-Reviewed Original ResearchProgression-free survivalIDH-mutant gliomasLow grade gliomasOverall survivalIDH-wtAlkylating chemotherapyGrade gliomasChemotherapy improves overall survivalMeta-analysis of randomized clinical trialsEffects of alkylating chemotherapyCompared to radiotherapyIDH-mutant tumorsWorld Health OrganizationIDH-wt glioblastomaIDH-wt gliomasMeta-analysisDiagnosis of glioblastomaIDH-wt tumorsIDH-wild typeRandomized clinical trialsRandom-effects modelMagnitude of benefitGlioblastoma trialsAnaplastic morphologyOS benefit
2023
FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s81-s82. DOI: 10.1016/j.ijrobp.2023.06.401.Peer-Reviewed Original ResearchPSA progression-free survivalMetastasis-free survivalMonths of GnRH agonistAbiraterone acetate/prednisoneSalvage radiotherapyGnRH agonistPre-planned analysisPost-RPStratification factorsProgression-free survivalPost-radical prostatectomyMedian follow-upSubgroup of patientsMulticenter randomized trialOne-sided type I errorPre-planned subgroup analysisStatistically significant benefitTwo-sided p-valuePelvic nodesOpen-labelPrimary endpointSecondary endpointsInvestigator-initiatedSafety profileAdverse eventsMGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy
Kinslow C, Rae A, Kumar P, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Yu J, Kachnic L, Cheng S, Wang T. MGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e117. DOI: 10.1016/j.ijrobp.2023.06.902.Peer-Reviewed Original ResearchMGMT promoter methylationMGMT promoter statusMGMT promoter methylation statusAssociated with poor survivalNational Cancer DatabaseOverall survivalUnmethylated MGMTPromoter methylation statusPromoter methylationPromoter statusAlkylating chemotherapyPoor survivalMultivariate Cox proportional hazards regression modelsResponse to alkylating chemotherapyProgression-free survivalCox proportional hazards regression modelsMethylation statusProportional hazards regression modelsReceipt of chemotherapyHazards regression modelsCourse of treatmentAnaplastic gliomasMGMT promoterCancer DatabaseDiagnosed gliomasMGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patientsAssociation of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy
Kinslow C, Mercurio A, Kumar P, Rae A, Siegelin M, Grinband J, Taparra K, Upadhyayula P, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Kachnic L, Yu J, Cheng S, Wang T. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. JAMA Oncology 2023, 9: 919-927. PMID: 37200021, PMCID: PMC10196932, DOI: 10.1001/jamaoncol.2023.0990.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse to alkylating chemotherapyMGMT promoter methylationMGMT promoter statusOverall survivalAnaplastic gliomasIDH-mutantAlkylating chemotherapyLow-gradePromoter methylationChemotherapy responseAssociated with progression-free survivalCohort studyPromoter statusAssociated with chemotherapy responseMultivariate Cox proportional hazards regression modelsClinical trials of patientsO6-methylguanine-DNA methyltransferaseCox proportional hazards regression modelsIDH wild-typeTrial of patientsIDH wild-type gliomasProportional hazards regression modelsO6-methylguanine-DNAProspective cohort studyFORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Journal Of Clinical Oncology 2023, 41: 303-303. DOI: 10.1200/jco.2023.41.6_suppl.303.Peer-Reviewed Original ResearchPSA progression-free survivalMetastasis-free survivalMonths of GnRH agonistAbiraterone acetate/prednisoneSalvage radiotherapyPre-planned analysisGnRH agonistPost-RPStratification factorsProgression-free survivalPost-radical prostatectomyMedian follow-upMonths of ADTSubgroup of patientsMulticenter randomized trialOne-sided type I errorPre-planned subgroup analysisStatistically significant benefitPelvic nodesOpen-labelPrimary endpointSecondary endpointsInvestigator-initiatedSafety profileAdverse events
2021
Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis
Gao S, Yu J, Park H, Decker R. Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e476-e477. DOI: 10.1016/j.ijrobp.2021.07.1324.Peer-Reviewed Original ResearchCurative-intent stereotactic body radiation therapyStereotactic body radiation therapyUpfront systemic therapyKarnofsky performance scoreProgression-free survivalSystemic therapyOverall survivalOligometastatic diseaseSequential therapyWorse survivalOligometastatic settingConcurrent therapyImproved survivalHigher Karnofsky performance scoreSingle-institution retrospective analysisOptimal timingCox proportional hazards modelExtracranial metastatic lesionsImproved overall survivalPrimary tumor locationMajority of patientsConcurrent systemic therapyMultivariate Cox analysisBody radiation therapyProportional hazards model
2020
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology 2020, 6: 1028-1037. PMID: 32496550, PMCID: PMC7273318, DOI: 10.1001/jamaoncol.2020.1271.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyProgression-free survivalSmall-cell lung cancer (SCLC) brain metastasesCell lung cancer brain metastasesCNS progression-free survivalLung cancer brain metastasesPropensity score-matched analysisMedian overall survivalCancer brain metastasesBrain metastasesOverall survivalStereotactic radiosurgeryCentral nervous system (CNS) progression-free survivalMedian CNS progression-free survivalSRS outcomesCentral nervous system progressionSmall cell lung cancerLimited brain metastasesMulticenter cohort studyDisease control statusCell lung cancerSingle-arm trialStandard of careLeptomeningeal progressionWBRT cohortRTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
Posadas E, Gay H, Pugh S, Morgan T, Yu J, Lechpammer S, Feng F. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery. Journal Of Clinical Oncology 2020, 38: tps5601-tps5601. DOI: 10.1200/jco.2020.38.15_suppl.tps5601.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalHigh-risk featuresSalvage radiotherapyBiochemical recurrenceRadical prostatectomyProstate cancerSystemic therapyAndrogen receptorYears of androgen deprivation therapyOccurrence of biochemical failureStandard androgen deprivation therapyRandomized phase II studyIndividualization of radiotherapyNon-steroidal anti-androgenPersistently elevated PSADisease control rateRecurrent prostate cancerSeminal vesicle invasionPara-aortic nodesSuspicious lymph nodesPatient-reported toxicityRisk of progressionOne-sided alphaElevated PSA
2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
Patrice G, Lester-Coll N, Yu J, Amdahl J, Delea T, Patrice S. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 97-106. PMID: 29029885, DOI: 10.1016/j.ijrobp.2017.08.041.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerThoracic radiation therapyProgression-free survivalIncremental cost-effectiveness ratioExtensive-stage small cell lung cancer patientsSmall cell lung cancerCell lung cancerStandard treatmentLung cancer trialsRadiation therapyOverall survivalLung cancerUS health care payer perspectiveLong-term survival benefitCancer trialsFavorable incremental cost-effectiveness ratiosProgressive metastatic diseaseHealth care payer perspectiveProportion of patientsBase-case analysisFollow-up intervalCost-effectiveness ratioMetastatic diseasePostprogression survivalPayer perspective